Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Hepatitis B Virus DNA Negativity Acts as a Favorable Prognostic Factor in Hepatocellular Carcinoma Patients

  • Li, Xing (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Zhong, Xiang (Shenzhen People's Hospital) ;
  • Chen, Zhan-Hong (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Xing, Yan-Fang (Department of Nephrology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Wu, Dong-Hao (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Chen, Jie (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Ma, Xiao-Kun (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Lin, Qu (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Wen, Jing-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Wei, Li (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Wang, Tian-Tian (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Ruan, Dan-Yun (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Lin, Ze-Xiao (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Wu, Xiang-Yuan (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Dong, Min (Department of Medical Oncology, the Third Affiliated Hospital of Guangzhou Medical University)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This retrospective study was aimed to investigate the efficacy of prophylactic agents in hepatocellular carcinoma (HCC) patients receiving TACE and compare the difference between lamivudine and entecavir. Materials and Methods: A consecutive series of 203 HBV-related HCC patients receiving TACE were analyzed including 91 patients given prophylactic agents. Virologic events, defined as an increase in serum HBV DNA level to more than 1 log10 IU/ml higher than the nadir level, hepatitis flares due to HBV reactivation and progression free survival (PFS) were the main endpoints. Results: Some 48 (69.6%) reached virologic response. Prophylaxis significantly reduced virologic events (8.8% vs 58.0%, p=0.000) and hepatitis flares (1.1% vs 13.4%, p=0.001). Patients presenting undetectable HBV DNA levels displayed a significantly improved PFS as compared to those who never achieved undetectable HBV DNA. Prophylaxis and e-antigen positivity were the only significant variables associated with virologic events. In addition, prophylaxis was the only independent protective factor for hepatitis flares. Liver cirrhosis, more cycles of TACE, HBV DNA negativity, a lower Cancer of the Liver Italian Program score, non-metastasis and no hepatitis flares were protective factors for PFS. Prophylactic lamivudine demonstrated similar efficacy as entecavir. Conclusions: Prophylactic agents are efficacious for prevention of HBV reactivation in HCC patients receiving TACE. Achievement of undetectable HBV DNA levels displayed a significant capability in improving PFS. Moreover, persistent tumor residual lesions, positive HBV DNA and hepatitis B flares might be causes of tumor progression in these patients.

Keywords

References

  1. Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. https://doi.org/10.1002/hep.24199
  2. Eltawil KM, Berry R, Abdolell M, et al (2012). Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre. HPB, 14, 162-70. https://doi.org/10.1111/j.1477-2574.2011.00420.x
  3. Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al (2011). Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos (t)ide analogues in clinical practice. Hepatology, 53, 1854-63. https://doi.org/10.1002/hep.24318
  4. Huang ZL, Luo J, Chen MS, et al (2011). Blood neutrophilto- lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol, 22, 702-9. https://doi.org/10.1016/j.jvir.2010.12.041
  5. Jang JW, Choi JY, Bae SH, et al (2004). Transarterial chemolipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol, 41, 427-35. https://doi.org/10.1016/j.jhep.2004.05.014
  6. Jang JW, Choi JY, Bae SH, et al (2006). A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology, 43, 233-40. https://doi.org/10.1002/hep.21024
  7. Kim IK, Kim BG, Kim W, et al (2012). Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virusinfected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother, 56, 5511-9. https://doi.org/10.1128/AAC.00821-12
  8. Lao XM, Luo G, Ye LT, et al (2013). Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int, 33, 595-604. https://doi.org/10.1111/liv.12112
  9. Lencioni R, Llovet JM (2010). Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, 30, 52-60. https://doi.org/10.1055/s-0030-1247132
  10. Li H, Hu Y, Li N, et al (2012a). Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. Asian Pac J Cancer Prev, 13, 1589-93. https://doi.org/10.7314/APJCP.2012.13.4.1589
  11. Li SH, Guo ZX, Xiao CZ, et al (2013a). Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev, 14, 4759-63. https://doi.org/10.7314/APJCP.2013.14.8.4759
  12. Li X, Dong M, Lin Q, et al (2013b). Comparison of current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. Asia Pac J Clin Oncol, 9, 86-92. https://doi.org/10.1111/ajco.12050
  13. Li X, Lin Q, Dong M, et al (2010). Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma, 51, 1678-85. https://doi.org/10.3109/10428194.2010.499486
  14. Li X, Xing YF, Lin Q, et al (2012b). The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol, 9, 350
  15. Liver EAftSot (2012). EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 57, 167-85. https://doi.org/10.1016/j.jhep.2012.02.010
  16. Lok AS, McMahon BJ (2009). Chronic hepatitis B: update 2009. Hepatology, 50, 661-2. https://doi.org/10.1002/hep.23190
  17. Murata S, Mine T, Ueda T, et al (2013). Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal, 2013, 479805.
  18. Nagamatsu H, Itano S, Nagaoka S, et al (2004). Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol, 99, 2369-75. https://doi.org/10.1111/j.1572-0241.2004.40069.x
  19. Scartozzi M, Faloppi L, Bianconi M, et al (2012). The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One, 7, 32653. https://doi.org/10.1371/journal.pone.0032653
  20. Torres HA, Davila M (2012). Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol, 9, 156-66. https://doi.org/10.1038/nrclinonc.2012.1
  21. Wang SY, Zhu WH, Vargulick S, et al (2013). Nausea and vomiting after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Asian Pac J Cancer Prev, 14, 5995-6000. https://doi.org/10.7314/APJCP.2013.14.10.5995
  22. Wang Y, Chen Y, Ge N, et al (2012). Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol, 19, 3540-6. https://doi.org/10.1245/s10434-012-2368-5
  23. Wu XY, Li X, Chen ZH, et al (2013). An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumour Biol, 34, 909-18. https://doi.org/10.1007/s13277-012-0626-6
  24. Yeo W, Chan HL (2013). Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol, 28, 31-7. https://doi.org/10.1111/j.1440-1746.2012.07280.x
  25. Yu SJ, Lee JH, Jang ES, et al (2013). Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization. Radiology, 267, 638-47. https://doi.org/10.1148/radiol.13121498

Cited by

  1. Preparation and Characterization of Anti-GP73 Monoclonal Antibodies and Development of Double-antibody Sandwich ELISA vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2043
  2. Analysis on Postoperative Efficacy of Radical Hepatectomy for Patients with Non-HBV/HCV Hepatocellular Carcinoma vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3479
  3. Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8665
  4. Dose-dependent pharmacokinetics and tentative identification of urine metabolites from an isosteviol derivative with anti-hepatitis B activity in rats vol.32, pp.9, 2018, https://doi.org/10.1002/bmc.4266
  5. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma pp.1573-2568, 2019, https://doi.org/10.1007/s10620-019-05543-4